Here are five things to know:
1. The acquisition closed at $1.045 billion less customary adjustments.
2. The Codman Neurosurgery portfolio includes devices for hydrocephalus, neuro-critical care and operative neurosurgery.
3. The Codman neurosurgery products generated about $370 million in 2016 revenue. This acquisition will situate Integra as a leader in neurosurgical products.
4. Integra possesses a portfolio of tissue ablation, dural repair and cranial stabilization products.
5. Additionally, Integra LifeSciences will soon divest its Camino ICP monitoring product line to Natus for $47.5 million. Natus will also gain U.S. rights associated with Integra’s fixed pressure shunts and Codman’s DURAFORM dural graft implant, standard EVD catheters and CSF collection systems.
More articles on devices:
Finally, a single-use, sterile packed ACDF kit simplified for OR efficiency, introducing the Zavation STERICERV Cervical Instruments Kit
TranS1, CU Innovations partner to bring surgeons’ spine concepts to market: 4 takeaways
Alphatec appoints former NuVasive executive as new executive chairman: 8 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
